Home Tools
Log in
Cart

Rebastinib

Catalog No. T2640   CAS 1020172-07-9
Synonyms: DCC2036, DCC 2036, DCC-2036

DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Rebastinib Chemical Structure
Rebastinib, CAS 1020172-07-9
Pack Size Availability Price/USD Quantity
2 mg In stock $ 40.00
5 mg In stock $ 63.00
10 mg In stock $ 97.00
25 mg In stock $ 181.00
50 mg In stock $ 265.00
100 mg In stock $ 397.00
200 mg In stock $ 597.00
1 mL * 10 mM (in DMSO) In stock $ 77.00
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.84%
Purity: 99.53%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
Targets&IC50 Abl-1 (WT):0.8 nM, Abl-1 (T315I):4 nM
In vitro In a xenograft mouse model bearing Ba/F3-BCR-ABL1T315I leukemia cells, DCC-2036 (100 mg/kg/day, p.o.) significantly inhibits BCR-ABL1 signaling and notably prolongs the lifespan of the mice.
In vivo DCC-2036 exhibits antiproliferative activity against Ba/F3 cells expressing either wild-type or mutant BCR-ABL1, with IC50 values ranging from 2 to 150 nM. It also inhibits the proliferation of the Ph+ cell line K562 (IC50: 5.5 nM) and effectively induces apoptosis in Ba/F3 and K562 cells expressing BCR-ABL1. Notably, DCC-2036 selectively inhibits BCR-ABL positive cells by significantly suppressing CML cell lines compared to non-CML leukemia cell lines. It demonstrates potent non-ATP-competitive inhibition against unphosphorylated and phosphorylated ABL1 (IC50: 0.8/2 nM), unphosphorylated and phosphorylated mutant ABL1T315I (IC50: 1.4/5 nM), and the activation loop mutant ABL1H396P (IC50: 4 nM). Additionally, DCC-2036 inhibits SRC family kinases SRC/LYN/FGR/HCK and receptor TKs KDR/FLT3/TIE2 (IC50: 34/29/38/40/4/2/6 nM).
Kinase Assay Assay of Abl1 kinase isoforms and determination of inhibitor potency: Activity of u-Abl1native is determined by following the production of ADP from the kinase reaction through coupling with the pyruvate kinase/lactate dehydrogenase system. In this assay, the oxidation of NADH (measured as a decreased A340 nM) is continuously monitored spectrophotometrically. The final reaction mixture (100 μL, in a 384-well Corning plate) is prepared as follows: An Abl1 kinase/coupled assay components mixture is prepared containing u-Abl1 kinase (1 nM), Abltide (EAIYAAPFAKKK, 0.2 mM), MgCl2 (9 mM), pyruvate kinase (~ 4 units), lactate dehydrogenase (~ 0.7 units), phosphoenol pyruvate (1 mM), and NADH (0.28 mM) in 90 mM Tris containing 0.1 % octyl-glucoside and 1 % DMSO, pH 7.5. Separately, an inhibitor mixture is prepared containing DCC-2036 serially diluted 3-fold in DMSO followed by dilution into buffer composed of 180 mM Tris, pH 7.5, containing MgCl2 (18 mM) and 0.2 % octyl-glucoside. Fifty μL of the inhibitor mixture is mixed with 50 μL of the above Abl1 kinase/coupled assay components mixture, which is then incubated at 30 °C for 2 hours before 2 μL of 25 mM ATP (500 μM, final) is added to start the reaction. The reaction is recorded every 2 minutes for 2.5 hours at 30 °C on a Polarstar Optima or Synergy2 plate reader. Reaction rate (slope) is calculated using the 1 to 2 hour time frame with reader's software. Percent inhibition is obtained by comparison of reaction rate with that of a DMSO control. IC50 values are calculated from a series of percent inhibition values determined at a range of inhibitor concentrations using GraphPad Prism. The kinase assay for Abl1T315I, p-Abl1native or Abl1H396P is assayed the same as above except that 2.2 nM Abl1T315I, 1 nM p-Abl1 native or 1.3 nM Abl1H396P is used. The above assay format is also used for kinases other than Abl1 with the exception of TIE2, for which a fluorescence polarization/Transcreener format is used.The assay conditions are the same as described above except that PolyE4Y (final 1 mg/mL) is used as the substrate and one hour preincubation is used.
Cell Research Ba/F3 cells or primary Ph+ leukemia cells are plated in triplicate in 96-well plates containing test compounds. After 72 hours, viable cells are quantified by Resazurin or MTT assay. Cells are diluted in medium to be added to each well of a 96-well tissue culture-treated plate. All cells are incubated overnight and maintained in a humidified atmosphere at 37 °C and 5% CO2. Cells are treated the following day. Serum-free medium is used during treatment with DCC-2036. MTT is used to assess the viability of cells following treatment. Aliquots of 20 mL of stock MTT solution are added to each well containing 200 mL of medium (10% final solution) and incubated with the cells for 2 hours. Following incubation the medium is removed and 200 mL of dimethylsulfoxide added to solubilize the formazan crystals. The absorbance is read on the plate reader at 550 and 690 nm. A subtraction analysis of the dual wavelength is performed (D550 to D690) to increase accuracy of the measuremen(Only for Reference)
Synonyms DCC2036, DCC 2036, DCC-2036
Molecular Weight 553.59
Formula C30H28FN7O3
CAS No. 1020172-07-9

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

Ethanol: 13 mg/mL (23.5 mM)

DMSO: 103 mg/mL (186.1 mM)

TargetMolReferences and Literature

1. Chan WW, et al. Cancer Cell. 2011, 19(4), 556-568. 2. Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 Feb 26;21(3):22.

TargetMolCitations

1. Cheng S, Jin P, Li H, et al. Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model. Frontiers in Pharmacology. 2021: 2866.

Related compound libraries

This product is contained In the following compound libraries:
Tyrosine Kinase Inhibitor Library Inhibitor Library Anti-Cancer Active Compound Library Anti-Cancer Clinical Compound Library Drug Repurposing Compound Library Kinase Inhibitor Library Anti-Neurodegenerative Disease Compound Library Anti-Cancer Drug Library Bioactive Compounds Library Max ReFRAME Related Library

Related Products

Related compounds with same targets
Costunolide Dasatinib BK60106 NSC 146109 hydrochloride BAY 61-3606 Hirsutine PNU-74654 Tetrac

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Dosage
mg/kg
Average weight of animals
g
Dosing volume per animal
ul
Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
Calculate Reset

TargetMolCalculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
=
X
X

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

X
=
X

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

=
/

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Rebastinib 1020172-07-9 Angiogenesis Apoptosis Cytoskeletal Signaling Tyrosine Kinase/Adaptors FLT Bcr-Abl Src CD135 inhibit Fms like tyrosine kinase 3 DCC2036 DCC 2036 DCC-2036 Inhibitor FLT3 Cluster of differentiation antigen 135 inhibitor

 

TargetMol